Ignite Creation Date:
2025-12-25 @ 2:49 AM
Ignite Modification Date:
2026-01-29 @ 2:06 PM
Study NCT ID:
NCT03259633
Status:
APPROVED_FOR_MARKETING
Last Update Posted:
2020-05-01
First Post:
2017-08-21
Is Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
An Intermediate Access Protocol for Selumetinib for Treatment of Neurofibromatosis Type 1
Sponsor:
AstraZeneca
Organization:
Conditions & Keywords Data
Conditions:
Conditions
| Condition Brief | Condition Text | View |
|---|---|---|
| None | NF type1 With Inoperable Plexiform Neurofibromas | View |
Keywords:
Keywords
| Keyword Brief | Keyword Text | View |
|---|---|---|
| None | Neurofibromatosis type1, | View |
| None | Plexiform Neurofibromas | View |
| None | inoperable, progressive/symptomatic plexiform neurofibromas (PN) without any alternative therapeutic options | View |
| None | mutation in the NF1 gene | View |
| None | Selumetinib | View |
| None | Early Access | View |
| None | Intermediate Access Protocol | View |